Lexeo Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held virtually on June 25, 2026. Lexeo Therapeutics, Inc. (LXEO) is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Class III Directors
- R. Nolan Townsend: Elected with 64,731,479 votes FOR.
- Brenda Cooperstone, M.D.: Elected with 48,792,570 votes FOR (notable withhold votes of 16,834,717).
- Paula HJ Cholmondeley: Elected with 64,652,712 votes FOR.
- Proposal 2: Ratification of Independent Auditor
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Voting results: 75,497,386 FOR, 55,579 AGAINST, 30,099 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. For further details on the proposals, the filing references the Proxy Statement filed on April 30, 2026.
Key Facts for Investor Verification
- Verify the significant number of withheld votes (approx. 16.8 million) for director Brenda Cooperstone, M.D., compared to other nominees.
- Confirm the total shares outstanding and broker non-vote counts (approx. 9.9 million) to assess voting power distribution.
- Review the April 30, 2026 Proxy Statement for context on the director nominees and auditor selection rationale.